All In Biotech

Drug Trial Radar · NCT05608590

What is the Best Moment for Performing an HSG in Women With a Unfulfilled Childwish

Tubal Flushing With Oil-based Contrast During HSG in Subfertile Women: Is Early Flushing Effective and Cost-effective as Compared to Delayed Flushing? - H2Oil-timing Study

Last checked: Nov 20, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 554 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

554

Planned (sponsor's estimate)

Start

Aug 22, 2019

Primary completion

Dec 1, 2025

Study completion Jan 1, 2026

Sponsor

Lead sponsor
Amsterdam UMC, location VUmcAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
First posted
Nov 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to determine whether direct tubal flushing with oil-based contrast at HSG incorporated in the fertility work-up results in 10% more ongoing pregnancies and a shorter time to pregnancy, which will therefore be effective and cost-effective compared to delayed tubal flushing 6 months after fertility work-up is completed in women at low risk for tubal pathology.

Conditions

  • Female Infertility

Interventions

  • Lipiodol UltraFluidDrug

    The investigational product is an oil-based contrast medium, Lipiodol® (Guerbet). Lipiodol® is a solution of ethyl esters of iodized fatty acids of poppy seed oil equivalent to 480mg I /ml and is a licensed contrast agent in the Netherlands (RVG 02806, see SmPC D2). The maximum amount of Lipiodol® per HSG procedure is 15 ml.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to live birthTime frame: 6 months
  2. Time to live birthTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Amsterdam AMC

    Amsterdam, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.